Belinostat in Treating Patients With Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well belinostat works in treating patients with
myelodysplastic syndromes. Belinostat may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth and by blocking blood flow to the cancer.